⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 30, 2026

Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse.

Luca Gattinoni Gabriele Inchingolo Dennis Christoph Harrer Alberto Susana Simone Puccio Dragana Slavkovic‐Lukic Danielle Natrakul Nicholas Strieder Christoph Heuser-Loy Jeremy Baldwin Jessica Fioravanti Yun Ji Sanjivan Gautam Chiara Suriano Azucena Martín-Santos Roland Christian Schelker Nisha Patel Jennifer Mann Stephanie Goff Lekha Mikkilineni James C Yang Mei Li M Kwong Rashmika Patel Michael Rehli Steven L. Highfill David F. Stroncek S A. Rosenberg Luca Biasco Enrico Lugli Jennifer N. Brudno James N. Kochenderfer

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to explore the dynamics of donor-derived stem cell memory CAR T cells following relapse after allogeneic hematopoietic stem cell transplantation (HSCT).
Examined in vivo dynamics of CAR T cells using a randomized trial design.
Evaluated outcomes in patients post-allogeneic HSCT.
Measured cell behavior across different time points after relapse.
Donor-derived CAR T cells exhibited unique in vivo dynamics compared to traditional T cells.
Significant differences in memory cell responses were observed during patient relapse phases.
Implications suggest a need for tailored CAR T therapy approaches based on these dynamic responses.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Investigates in vivo dynamics of CAR T cells post-relapse in HSCT, indicating therapeutic potential.

Abstract

cells as a promising platform for next-generation CAR T cell therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gattinoni et al. (2026) studied this question.

synapsesocial.com/papers/69f837233ed186a739981376 https://doi.org/10.1016/j.cell.2026.03.047

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Enhancing Graft-versus-Leukemia Responses by donor-derived CAR-modified CD8+ Memory Stem T cellsHuman Clinical Trial · 2026
2Persistent CAR-T donor cells contribute to mixed chimerism with cytopenia after CAR-T-bridged allo-HSCT: rescue by CAR-target-knockout DLI in three casesOriginal Research · 2026
3In Vivo clonal dynamics of alloreactive CAR T cells reveal mechanisms limiting gvhd risk following allogeneic CAR T cell therapy2025
4Recipient-derived vs. donor-derived CAR-T-cell therapy in relapsed B-cell acute lymphoblastic leukemia patients after transplantation: A multi-center retropective study2025 · 2 citations
5Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15Original Research · 2014 · 750 citations

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation2013
CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies2023
Abstract 4020: Donor-dependent anti-tumoral efficacy of human CD19 CAR T cells in a leukemic xenograft mouse model2024

More from National Institutes of Health

More from National Cancer Institute

More from Center for Cancer Research

More from University of Regensburg

More from National Institutes of Health Clinical Center

More from Palo Alto University

More from University Hospital Regensburg

More from Leibniz Association

More from IRCCS Humanitas Research Hospital

More from Institute of Infection and Immunity

More from Leibniz Institute for Immunotherapy